EUVIMEDEUVIMED entdecken
Crossref

Leveraging genetic predictors of factor XI levels to anticipate results from clinical trials

Iyas Daghlas iD, Dipender Gill

European Journal of Neurology · 2023

DOI: 10.1111/ene.15820 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2023. Verfasst von Iyas Daghlas und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Venous Thromboembolism, Thrombosis, Ischemic Stroke. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Factor XI (FXI) is a promising therapeutic target for the prevention of thrombotic disease without increasing bleeding risk.

Methods

We performed Mendelian randomization (MR) analyses to investigate the association of genetically predicted reductions in FXI levels with risk of venous thromboembolism, ischemic stroke, bleeding outcomes, and lifespan.

Results

Genetically predicted reductions in FXI levels were associated with lower risk of ischemic stroke (odds ratio per 1 standard deviation (SD) lower serum FXI 0.90, 95% confidence interval 0.87–0.93, p = 1.59 × 10 −11 ), and venous thromboembolism (0.54, 0.49–0.59, p = 2.13 × 10 −39 ) but did not associate with increased bleeding risk ( p > 0.16). Genetically predicted reductions in serum FXI levels associated with longer lifespan (0.37 years per 1 SD lower serum FXI, 0.13–0.61, p = 0.003).

Conclusions

These genetic data support FXI as a potentially efficacious and safe therapeutic target and anticipate positive results from ongoing phase 3 clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismThrombosisIschemic StrokeHumansFactor XIHemorrhage

Stichwörter der Autor:innen

FXIMendelian randomizationfactor XIstrokevenous thromboembolism

Substanzen

Factor XI

Autor:innen und Institutionen

  • Department of Neurology, University of California San Francisco, San Francisco, California, USA.
  • Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

ORCID-Profile: Iyas Daghlas

Zitieren

APA

Daghlas, I., & Gill, D. (2023). Leveraging genetic predictors of factor XI levels to anticipate results from clinical trials. European Journal of Neurology. https://doi.org/10.1111/ene.15820

Vancouver

Daghlas I, Gill D. Leveraging genetic predictors of factor XI levels to anticipate results from clinical trials. European Journal of Neurology. 2023. doi:10.1111/ene.15820

BibTeX
@article{Daghlas2023,
  author = {Daghlas, Iyas and Gill, Dipender},
  title = {Leveraging genetic predictors of factor XI levels to anticipate results from clinical trials},
  journal = {European Journal of Neurology},
  year = {2023},
  doi = {10.1111/ene.15820}
}
Kostenlos starten →